Précis. Among its many roles in cancer, c-MYC may also serve as a molecular switch of the character of the tumor microenvironment, as illustrated by its ability to convert responses to a pro-inflammatory factor from suppressive to supportive for tumor growth. 
Introduction
Clinical and epidemiological data has associated an inflammatory microenvironment with cancer development (1) . Most tumors show evidence of infiltrating immune and inflammatory cells, and chronic inÀammatory disorders are known to increase the overall risk of cancer development. Importantly, inflammation is often observed during early stages in the transformation process, however, there remains debate over whether the inflammatory cells and the cytokines they produce in the developing tumor microenvironment act to inhibit or facilitate tumor development (2) . The IL-6 family of cytokines, which includes IL-6, Oncostatin M (OSM) IL-11, leukemia inhibitory factor (LIF), cardiotrophin-1 (CT-1), ciliary neurotrophic factor (CNTF), and cardiotrophin-like cytokine (CLC) are secreted by immune cells, stromal cells, and epithelial cells, and regulate diverse processes (3) . Although each of the IL-6 family cytokines signals through a distinct receptor complex, they share the gp130 receptor subunit (4) . Activation of gp130 kinase activity results in activation of the STAT3 transcription factor, and the MitogenActivated Protein Kinase (MAPK) and Phosphatidylinositol 3-Kinase (PI3K) signaling cascades (4) . The gp130 family of cytokines are highly pleiotropic in normal development, yet an overlapping role for these cytokines in cancer continues to emerge, with studies now implicating autocrine and paracrine IL-6, LIF and OSM-mediated gp130 activation as important mediators of tumor progression and metastasis (4-7).
OSM was originally identified based upon its ability to inhibit the proliferation of melanoma cells (8) , an observation that has since been confirmed in breast cancer cells, lung cancer cells, glioma, and neuroblastoma (3) . In humans, OSM and LIF bind to the LIFȕ-gp130 receptor, while OSM binds uniquely to the OSMRȕ-gp130 receptor. (3, 9) . The growth inhibitory properties of OSM are engaged by the STAT3-mediated suppression of the c-MYC gene, and the resulting hypothesis from early studies of OSM was that OSM signaling was tumor suppressive and may be exploited as a potential cancer therapy (10, 11) . However, OSM stimulates the proliferation of normal dermal fibroblasts, Kaposi's sarcoma cells, and plasmacytoma cells, and can promote breast cancer cell migration and invasiveness (3, 12) . In addition, subsequent studies have confirmed the paradoxical effects of OSM in normal and preneoplastic lung epithelial cells, with OSM suppressing the proliferation of normal lung epithelial cells, while increasing the proliferation of preneoplastic lung cells (13) . To date, an explanation for the contradictory responses to OSM remains elusive.
We describe here, the effects of OSM on human mammary epithelial cells (HMEC) at various stages of neoplastic transformation. Since STAT3 is an oncogene, we hypothesized that sustained STAT3 activation (by persistent gp130 activation) would promote a p53-and p16-independent oncogene-induced senescence (OIS) similar to RAS, MOS or STAT5 (14) (15) (16) .
However, we found that the OSM-mediated growth arrest occurs independently of the p16 and p53 tumor suppressors, and required efficient down-regulation of c-MYC gene expression by STAT3. Inhibition of STAT3 using a dominant-negative protein or an shRNA targeting STAT3 expression or expression of c-MYC from a constitutive promoter prevented efficient OSMmediated growth suppression. Importantly, not only did HMEC constitutively expressing c-MYC fail to undergo an arrest in response to OSM, they actually gained the capacity for anchorageindependent growth (AIG), a hallmark of transformed cells. The transformed phenotype conferred by OSM treatment was dependent on PI3K-AKT signaling, since inhibition of either PI3K or AKT suppressed OSM-mediated AIG. Our results provide an understanding of the paradoxical nature of OSM signaling, and suggest that c-MYC is an important molecular switch that alters the cellular response to OSM from tumor suppressive to tumor promoting.
Understanding the tumor suppressive barriers that are engaged during the OSM-mediated growth arrest may provide a foundation for future therapies aimed at reengaging these hidden limits to proliferation as a cancer therapy.
Methods
Cell lines and culture conditions. Finite lifespan, post-selection HMEC 48R, batch S (17) and 184 were provided by Dr. Martha Stampfer (Lawrence Berkeley National Laboratory). The nonimmortalized 48R cells were expanded and used between passage 10 and passage 16 for the studies performed here and the non-immortalized 184 cells were used between passage 9 and passage 15. Cells were grown in a humidified atmosphere containing 5% CO 2 (20) . pWZL-puro-MF-p110a (21) and other shRNA constructs and protocols for virus production and infection of cells have been described elsewhere (22) . Western analysis. Whole cell extracts were prepared by incubating cell pellets in lysis buffer as described (21) . Equal protein amounts were separated by SDS-PAGE (8-12.5% acrylamide) and transferred to PVDF membranes (Millipore), and Immunoblotted with the indicated antibodies.
Antibodies to p53 (DO-1), STAT3 (C-20), p21 (C19) were from Santa Cruz Biotechnology; the phospho-STAT3 (Tyr705) was obtained from Cell Signaling; the antibody to Actin (C4) was from Neomarkers; and antibodies to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and HDM2 (2A10) were from Calbiochem. Primary antibodies were detected with goat anti-mouse or goat anti-rabbit conjugated to horseradish peroxidase.
Results
OSM treatment induces a p16-and p53-independent growth arrest in human mammary epithelial cells. OSM has been reported to induce growth arrest or proliferation in a variety of normal and tumor-derived cancer cells, although the reason for the divergent responses is not understood (3). We reasoned that differences in key tumor suppression pathways may account for the conflicting results obtained with OSM in previous studies. For example, the growth arrest engaged following dysregulated oncogene expression, including constitutive STAT5, RAS, and MOS (17) (18) (19) (20) , can be inhibited by disabling p16 or molecular components of the DNA damage response (DDR), including ATM, CHK2 or p53. Since STAT3 is an oncogene, we hypothesized that sustained STAT3 activation would also promote a p53-dependent oncogene-induced growth arrest similar to STAT5, RAS, or MOS. To test this hypothesis, an shRNA targeting p53 was expressed in post-selection HMEC (referred to here as 48RS), which lack p16 protein expression due to promoter methylation (23) , and the response to persistent STAT3 activation was examined following long-term OSM treatment.
The absence of p53 expression and function was confirmed in cells expressing the p53-shRNA using Western analysis and functional growth assays [Supplemental Fig. 1 and (24)].
After confirming the suppression of p53, the control 48RS and shp53-48RS were treated with OSM and growth was assessed after 10 days. Treatment of both 48RS and shp53-48RS cells resulted in a similar level of STAT3 phosphorylation (P-STAT3; Fig. 1A ), an enlarged, vacuolated cellular morphology (Fig. 1B) , and an 80% decrease in cell number relative to untreated cells, similar to TGF-β treatment (Fig. 1C ). In addition, the OSM treated cells had considerable senescence-associated (SA) β-galactosidase activity resulting in the characteristic blue staining upon incubation of the OSM-treated cells with bromo-chloro-indolyl-
The presence of SA β-galactosidase activity is consistent with our conclusion that the decrease in cell number following OSM treatment was due to a decrease in proliferation. Moreover, we confirmed that the decrease in cell number observed following OSM treatment was not due to increased cell detachment, as has been reported for invasive breast cancer cells treated with OSM (12, 25) , by measuring the number of detached cells in control and OSM-treated cultures 48 hours after treatment (Supplemental Fig. 2 ).
To further define the kinetics of the OSM-mediated arrest, a time-course experiment was performed in which cells were treated with OSM for 2 to 9 days. A decrease in proliferation was observed with as little as 48 hours of OSM treatment, and was increasingly evident throughout the time-course (Supplemental Fig. 3 ). We conclude that unlike the arrest observed following constitutive STAT5 activation (15) , which is dependent on ATM and p53 signaling, persistent STAT3 activation induced by OSM engages a p53-independent growth arrest. Since most tumors have inactivated p53 signaling, understanding this unique p53-independent arrest engaged by OSM may provide opportunities for novel therapies aimed at re-engaging this proliferative barrier as a cancer therapy.
OSM suppresses HMEC growth more efficiently than IL-6. OSM is a member of the Interleukin-6 (IL-6) family of cytokines, which signal through a common gp130 receptor subunit (4). IL-6 itself has been extensively implicated in cancer and is also a known activator of STAT3 (6) . To compare OSM and IL-6, and determine whether IL-6 also suppresses the growth of HMEC, the 48RS-shp53 cells were treated with IL-6 (with or without soluble IL-6 receptor) at 50 or 100 ng/mL, and compared to OSM treatment at 2, 10, or 100 ng/mL after 10 days. Again, OSM treatment induced a significant growth inhibition (80% inhibition at 10 ng/mL and 95% inhibition at 100 ng/mL), while IL-6 treatment induced only a moderate growth inhibition (10% inhibition at 50 ng/mL and 50% inhibition at 200 ng/mL; Fig. 2A ). In agreement with the results obtained using standard 2-dimensional culture, acini formation of 48RS-shp53 cells in 3-dimensional laminin-rich basement membrane (Matrigel) was strongly inhibited by OSM (70% inhibition at 25 ng/mL) and weakly inhibited (25% inhibition at 25 ng/mL) by IL-6 (Supplemental Fig. 4 ). In addition, IL-6 treatment resulted in a less robust phosphorylation of STAT3-Y705 relative to OSM, with maximal STAT3 phosphorylation observed at the lower 50 ng/mL dose (Fig. 2B) . A time-course comparison of OSM (10 ng/mL) and IL-6 (50 ng/mL) treatment demonstrated that STAT3 phosphorylation was strongly induced 15 minutes after OSM treatment, and to a lesser extent after IL-6 treatment (Fig. 2C ). However, after one hour of OSM or IL-6 treatment there was a significant decrease in phosphorylated STAT3, consistent with the negative feedback regulation of STAT3 by SOCS3 and PIAS3 [ Fig. 2C ; (26, 27) ]. In both the long-term and short-term analyses, IL-6 was clearly less efficient at inducing and maintaining STAT3 phosphorylation, even when used at a significantly higher dose, likely explaining the decreased ability of IL-6 to suppress growth. Furthermore, while the suppression of STAT3 phosphorylation is robust and occurs rapidly (within 1 hour), sustained STAT3 phosphorylation is evident in the OSM-treated samples between 1 and 10 days ( Fig. 2C and 2D ).
OSM-mediated growth suppression is STAT3-dependent. Activation of the OSM/gp130
receptor results in the phosphorylation of STAT3, which permits its dimerization and movement to the nucleus, where it transcriptionally regulates a myriad of genes (6, 28) . (Fig. 4C) . We confirmed that constitutive c-MYC expression did not prevent the phosphorylation of STAT3-Y705 by OSM (Supplementary Fig. 6 ). Taken together, our results suggest that downstream STAT3 effects, rather than upstream gp130 receptor or JAK kinase activity, were inhibited by constitutive c-MYC expression.
We have recently shown that c-MYC expression contributes to a transformed phenotype when combined with an aberrant growth signal, such as mutant RAS-G12V (24) . We hypothesized that once the OSM/STAT3-mediated growth arrest was dismantled, additional OSMR/gp130-mediated signaling (which includes PI3K-ATK or MAPK) might cooperate to transform the HMEC. To test this hypothesis, the shp53-48RS derivatives were plated into soft agar with or without OSM and anchorage-independent growth (AIG), a property associated with malignant transformation, was assayed. IL-6 treatment was also tested for comparison. In the absence of c-MYC expression, there was no observable AIG, whereas c-MYC expression conferred a slight increase in AIG (Fig. 4D) 
ng/mL or 25 ng/mL OSM induced significant AIG, with a slight inhibition of AIG at the higher dose of OSM (Fig. 4D) . In contrast to the weak effect observed with IL-6 in the growth suppression assays, IL-6 efficiently induced AIG following treatment with either 10 or 25 ng/mL. Combined addition of OSM and IL-6 did little to either enhance or inhibit AIG (Fig. 4D) .
To confirm that our findings are not specific to one HMEC culture, we repeated our experiments in a second post-selection strain derived from an independent reduction mammoplasty, referred to here as patient 184. An shRNA targeting p53 was delivered to the 184 HMEC and Western analysis confirmed the knockdown of p53 protein levels in the shp53-184 and the abrogation of p53-dependent transactivation of target genes HDM2 and p21 in response to Nutlin-3, a p53 stabilizing compound ( Supplementary Fig. 7 ). Similar to the 48RS derivatives, both control 184 and 184-shp53 cells were growth inhibited by OSM treatment, and largely insensitive to IL-6 treatment ( Fig. 5A and 5B). The growth of shp53-184 cells expressing c-MYC from a constitutive promoter (shp53/MYC-184) was unaffected by either OSM or IL-6.
Upon plating the shp53-184 and shp53/MYC-184 cells into agar to assess AIG, we again observed that both OSM and IL-6 cooperated with c-MYC to promote a transformed phenotype.
As expected, control shp53-184 lacking constitutive c-MYC expression failed to form colonies when treated with OSM or IL-6. Our collective results using HMEC from two independent patients suggest that c-MYC is an important molecular switch that alters the cellular response to OSM from tumor suppressive to tumor promoting, providing an understanding of the paradoxical nature of OSM signaling.
OSM-mediated transformation of c-MYC expressing HMEC is PI3K-AKT-dependent.
Following ablation of the p16 and p53 tumor suppressors, and constitutive c-MYC expression, 48RS HMEC can be readily transformed by numerous aberrant growth signals, including mutant RAS-G12V (24, 31). We hypothesized that, once c-MYC was constitutively expressed and unable to be suppressed by OSM/STAT3, the additional, well-documented growth promoting properties of STAT3 would serve to drive HMEC transformation. To test this, shp53/MYC-48RS cells expressing wild-type or constitutively active STAT3 (STAT3-C), or RAS-G12V (used as a positive control (24)) were created and plated into soft agar. Surprisingly, expression of either STAT3 protein failed to promote AIG in the shp53/MYC-48RS cells (Fig. 6A ). In addition, (Fig. 6B and 6C) . In contrast, expression of CA-PI3K with c-MYC promoted AIG as efficiently as RAS-G12V even in the absence of OSM. Moreover, addition of OSM to shp53/PI3K/MYC-48RS or shp53/RAS/MYC-48RS cells was unable to facilitate greater AIG compared to the absence of OSM (Fig. 6B and   6C ). This observation argues that OSM functions to enhance AIG by activating PI3K signaling, which cannot be elevated beyond the activity imparted by CA-PI3K or RAS-G12V. In contrast to CA-PI3K, co-expression of CA-MEK with c-MYC was unable to promote AIG alone, but again, resulted in an increase in AIG following OSM treatment similar to the control cells ( (Fig. 6D) . Taken together, we propose that the combination of constitutive c-MYC expression and OSM-mediated PI3K-AKT signaling, but not constitutively active STAT3, cooperate to drive a transformed phenotype.
The presence of OSM has been reported in the tumor interstitial fluid (TIF) that perfuses the breast carcinoma microenvironment (32) . Furthermore, in a recent microarray experiment to identify stromal gene expression signatures, Finak et. al performed laser capture microdissection to isolate tumor stroma and matched normal stroma from human breast cancers (33) . Analysis of their expression data identified OSM mRNA as significantly upregulated in the tumor-associated stroma compared to normal stroma (Fig. 7A) . Furthermore, within the tumor stroma, higher OSM mRNA levels correlated a significant increase in the risk of tumor recurrence ( Fig. 7B; (33)). Our cell culture data suggests that the presence of OSM within a developing tumor The presence of OSM in the breast and prostate tumor microenvironment has been documented, with increasing OSM protein concentrations observed during cancer progression (7, 32) . OSM in the microenvironment may originate from tumor-associated macrophages, neutrophils, tumor cells, or additional cancer stromal components (2, 33, 35) , and may contribute to tumor progression in a number of ways. First, OSM mRNA is significantly upregulated in microdissected breast tumor-associated stroma compared to normal stroma, and those tumors harboring the highest level of stromal OSM mRNA have the greatest risk of tumor recurrence [ Fig. 7; (33) ]. Second, OSM-positive macrophages are predominantly localized at the advancing, infiltrative margins of carcinomas, which may implicate OSM in tumor invasion (36) . Third, in addition to OSM in the tumor microenvironment, the OSM receptor (OSMR) is also frequently overexpressed in cervical and ovarian carcinomas, and is associated with adverse clinical outcome (37, 38) . Finally, the widely used chemotherapy drug cisplatin induces peritoneal and bone marrow-derived macrophages to induce significant OSM secretion (39, 40 In a recent study, we defined a p16-and p53-independent senescence response that was engaged in HMEC upon oncogenic RAS expression. Similar to our findings with OSM, RASmediated senescence could be prevented by constitutive c-MYC expression (24) . We suggest (Fig. 7C) . We originally hypothesized that STAT3 activation would cooperate with c-MYC to promote a transformed phenotype, given the numerous STAT3 target genes with oncogenic properties (18) . However, it was clear that neither wild-type or constitutively active STAT3 were sufficient to take the place of OSM in promoting a effectively suppressed will dictate whether cells arrest or continue proliferating. Once a cell dismantles the tumor suppressive response engaged by persistent STAT3 activation and continues proliferating in the presence of OSM, the additional signaling emanating from PI3K, MYC, and STAT3 will allow for premalignant expansion and ultimately full transformation (Fig.   7C ). While our studies show that STAT3 is not sufficient to cooperate with c-MYC in HMEC transformation, it is clear that many tumor-derived cells have high levels of phosphorylated STAT3 and require sustained STAT3 activity for survival. STAT3 may be responsible for inhibiting apoptosis, or promoting invasion and metastasis, due to BCL-xL and matrix metalloproteinase induction, respectively. In the experiments described here, we did not measure these STAT3 effectors and therefore cannot define their involvement in our model. ACTIN (as a loading control) . B, shp53-48RS cells were treated with OSM (25 ng/mL) or left untreated for 96 hours and stained for the presence of senescence-associated β-galactosidase activity (which results in blue coloration). C, Control 48RS and shp53-48RS cells were treated with OSM (10 ng/mL) or TGF-ȕ (10 ng/mL) for 10 days and cell number was quantified using a Coulter counter. 
